Third Harmonic Bio, Inc.

    Third Harmonic Bio, Inc.

    NNASDAQ:THRD
    - -
    USD
    - -
    - -
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    - -
    - -
    Basic EPS, GAAP
    -0.49
    -1.13
    -2.62
    -0.78
    - -
    -1.26
    Free Cash Flow per Basic Share
    -0.35
    -0.6
    -2.6
    -0.52
    - -
    -0.99
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -0.71
    -1.84
    -6.21
    -2.88
    - -
    -4.15
    Tangible Book Value per Share
    -0.7
    -1.78
    21.53
    6.79
    - -
    6.45
    Basic Weighted Avg Shares
    26
    26
    13
    40
    - -
    42
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    - -
    - -
    - -
    - -
    - -
    - -
    Net Income, GAAP
    -13
    -30
    -35
    -31
    -45
    -53
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Working Capital
    6
    123
    287
    267
    283
    271
    LT Debt
    - -
    - -
    4
    3
    2
    2
    Total Equity
    -18
    -47
    289
    269
    285
    273
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    ST Debt
    1
    1
    1
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    3
    2
    2
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    45
    45
    45
    Market Capitalization
    551
    419
    147

    Working Capital

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    Total Current Assets
    300
    291
    276
    Cash, Cash Equivalents & STI
    296
    285
    272
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    7
    7
    5
    Payables & Accruals
    4
    3
    4
    ST Debt
    1
    1
    1
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    5.97%
    Free Cash Flow
    - -
    - -
    67.59%
    Net Income, GAAP
    - -
    - -
    47.51%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.23
    -0.19
    -0.19
    - -
    -0.78
    2024
    -0.2
    -0.26
    -0.33
    - -
    - -
    2025
    -0.35
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

    • globenewswire.com

      Third Harmonic Bio Announces Plan of Liquidation and Dissolution

    • globenewswire.com

      Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

    • zacks.com

      Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    • zacks.com

      Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?

    • zacks.com

      Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)

    • benzinga.com

      Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape

    • globenewswire.com

      Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

    • globenewswire.com

      Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference

    • zacks.com

      Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade

    • globenewswire.com

      Third Harmonic Bio to Participate in Upcoming Investor Conferences in November

    • globenewswire.com

      Third Harmonic Bio Announces Third Quarter 2024 Financial Results

    • globenewswire.com

      Third Harmonic Bio to Participate in Upcoming Investor Conferences in September

    • globenewswire.com

      Third Harmonic Bio to Participate in Upcoming Investor Conferences

    • globenewswire.com

      Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

    • globenewswire.com

      Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference

    • globenewswire.com

      Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update

    • globenewswire.com

      Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

    • globenewswire.com

      Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

    • globenewswire.com

      Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference